 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Anti-CCR4 monoclonal antibody Mogamulizumab combined with nivolumab in the treatment of locally advanced or metastatic solid tumors

Clin Cancer Res: Anti-CCR4 monoclonal antibody Mogamulizumab combined with nivolumab in the treatment of locally advanced or metastatic solid tumors

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

verapamil 240 mg

solid foam insulation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Programmed cell death-1 (PD-1) is a regulatory receptor usually expressed on malignant tumor cells.
It helps tumor cells achieve immune escape by down-regulating the activation of T cells and B cells
.

At present, the use of drugs such as nivolumab and pembrolizumab for PD-1 suppression immunotherapy has been recognized as a major progress in cancer treatment

immunity

Mogamulizumab is an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (eTreg)
.

This study aims to clarify the safety, anti-tumor activity and pharmacodynamics of Mogamulizumab combined with the checkpoint inhibitor nivolumab in locally advanced or metastatic solid tumors

Mogamulizumab is an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (eTreg) Mogamulizumab is an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (eTreg)

This is a multicenter, dose-exploratory (phase I) and dose-expandable (phase II) study, recruiting patients with locally advanced or metastatic solid tumors
.

The phase I trial dose is: Mogamulizumab 1mg/kg·week in the first course of treatment, then changed to 1 mg/kg·2 weeks, plus nivolumab 240 mg/2 weeks

Time to remission (TTR), duration of remission (DOR), progression-free survival (PFS) and overall survival (OS)

A total of 114 patients received Mogamulizumab (1 mg/kg) + nivolumab (240 mg) treatment, 4 of whom were in phase I and 110 were in phase II.
All were included in the safety and efficacy analysis
.

Mogamulizumab combined with nivolumab showed acceptable safety and tolerability

The objective response rate reached 10.

Mogamulizumab combined with nivolumab did not improve the therapeutic effect of locally advanced or metastatic solid tumors

Original source:

David S.

Mogamulizumab in Combination with Nivolumab in a Phase I / II Study of Patients with Locally Advanced or Metastatic Solid Tumors in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.